Literature DB >> 10837406

CD40 expressed on human melanoma cells mediates T cell co-stimulation and tumor cell growth.

G Pirozzi1, V Lombari, D Zanzi, F Ionna, M L Lombardi, S Errico, G Ruggiero, C Manzo.   

Abstract

CD40 is a 50 kDa molecule, a member of the tumor necrosis factor/nerve growth factor receptor family. It is expressed on B cells, monocytes, dendritic cells and various malignant cells. While the critical relevance of this molecule in T cell-dependent B cell activation is already established, the biological role of CD40-CD154 interaction in non-hematopoietic cells is still unknown. Here we show that CD40 is functionally expressed on human melanoma-derived cell lines. No correlation between surface CD40 expression and the origin of the cell line, primary versus metastatic, was observed. Melanoma cells were shown to be able to co-stimulate TCR-triggered human T cells; moreover, because they do not express CD80 or CD86 co-stimulatory structures, the involvement of additional pathways have to be postulated. We have identified CD40 as one of the molecules involved in melanoma cell-mediated co-stimulation of anti-CD3-triggered human CD4(+) T lymphocytes. In addition, a CD40-dependent pathway, able to enhance tumor cell proliferation at low serum concentrations, in vitro, has been shown to be functional in human melanoma cell lines.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10837406     DOI: 10.1093/intimm/12.6.787

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  4 in total

1.  Expression and functional role of CRIPTO-1 in cutaneous melanoma.

Authors:  A De Luca; L Lamura; L Strizzi; C Roma; A D'Antonio; N Margaryan; G Pirozzi; M-Y Hsu; G Botti; E Mari; M J C Hendrix; D S Salomon; N Normanno
Journal:  Br J Cancer       Date:  2011-08-23       Impact factor: 7.640

2.  BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.

Authors:  Luca Paoluzzi; Douglas Hanniford; Elena Sokolova; Iman Osman; Farbod Darvishian; Jinhua Wang; James E Bradner; Eva Hernando
Journal:  Cancer Med       Date:  2016-05-11       Impact factor: 4.452

Review 3.  Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy.

Authors:  Chi Yan; Ann Richmond
Journal:  Mol Cancer       Date:  2021-11-10       Impact factor: 27.401

4.  Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade.

Authors:  Chi Yan; Nabil Saleh; Jinming Yang; Caroline A Nebhan; Anna E Vilgelm; E Premkumar Reddy; Joseph T Roland; Douglas B Johnson; Sheau-Chiann Chen; Rebecca L Shattuck-Brandt; Gregory D Ayers; Ann Richmond
Journal:  Mol Cancer       Date:  2021-06-06       Impact factor: 41.444

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.